Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? Dendreon Corporation
Dendreon shares soared 21 percent on more six-times the average daily volume Friday. Sanford C. Bernstein & Co. analyst Geoffrey Porges recently raised his peak revenue forecast for Provenge, the company’s prostate cancer drug, to $799 million by 2017, his previous forecast was $580 million.
Going forward ... (see research report)
Subscribe to News Feeds